lipid
Explore 2 research publications tagged with this keyword
Publications Tagged with "lipid"
2 publications found
2019
1 publicationContribution of Nanotechnology In the Improvement of the Anti-Inflammatory activity of Shea butter.
Unrefined shea butter is a vegetable fat that can be used for its anti-inflammatory properties related to its unsaponifiable fraction but also as excipient for various forms. In this study, the aim was to see how to take advantage of this dual status in order to improve the anti-inflammatory activity of shea butter through nanotechnology. In other words, it was to test the hypothesis of an improvement of the anti-inflammatory activity of unrefined shea butter when used in the form of nanoparticles and gel / nanoparticle system. The nanoparticles were prepared by a phase inversion method and had an average size of 400 nm with a poly dispersion index of 0.416, a zeta potential between -5 and -7mV and a pH around 5.3-5.4. The gel / nanoparticle complex was obtained by mixing the nanoparticles with a gel based on polyethylene glycol, water and HydroxyPropyl Methylcellulose. The mouse ear edema test was implemented for the evaluation of the anti-inflammatory activity and the results showed a clear improvement of the latter. Indeed, the ratios (R) between the percentage inhibition of the anti-inflammatory activity (I) and the real percentage of shea butter used in the various preparations are respectively: crude shea butter (I = 62.52%; R = 0.62), nanoparticles (I = 60.80%, R = 1.05) and gel / nanoparticle complex system (I = 52.41, R = 6.38) (for the latter, the proportion of nanoparticles in the complex system was 4/24). Keywords: Shea butter, phase inversion, lipid, nanoparticles, nanoparticle/gel complex, anti-inflammatory activity
2013
1 publicationEvaluation of Antihyperglycemic and Lipid Lowering Activity of Caralluma Fimbriata in Diabetes Induced rats.
This study evaluates antihyperglycemic and lipid lowering activity of Caralluma fimbriata in dexamethasone induced diabetic rats. Serum glucose and lipid lowering activity of Caralluma fimbriata was tested at dose of 50 mg/kg and 100 mg/kg per oral route against dexamethasone induced hyperlipidemia and hyperglycemia in Spraugue-Dawley (SD) rats. On day 11, blood was collected for the estimation of serum glucose and lipids. Caralluma fimbrita in both the doses significantly decreased Serum glucose, total cholesterol, triglyceride and LDL as compared to dexamethasone only group (P
